Despite the drug having a 90-minute half-life, patients maintained and even saw continued improvement eight months after stopping the 12-week treatment. This suggests the drug facilitates genuine neural repair and rewiring, rather than offering only temporary symptomatic relief that requires continuous dosing.

NervGen is expanding its drug's potential by partnering with the Department of Defense. Walter Reed tests it for traumatic brain injury, and the Air Force for hearing loss. This strategy provides non-dilutive funding and validation for new indications, broadening the company's platform with minimal internal R&D spend.

The CEO of NervGen explicitly states his goal is to commercialize their spinal cord injury drug independently, not to position the company for an acquisition. This long-term, mission-driven focus on getting a drug to market shapes strategic decisions and contrasts with a common build-to-sell mentality in biotech.

Contrary to the long-held belief that nerves don't regrow, scientists have achieved 100% regeneration of crushed optic nerves in mice, restoring their sight. This groundbreaking success, far surpassing previous 5% regrowth rates, opens the door to treating spinal cord injuries and neurodegenerative diseases like ALS.

Stoke highlights its Open Label Extension (OLE) study as a critical asset. It provides rare longitudinal data, now approaching four years, demonstrating that patients with Dravet syndrome get progressively better "year on top of year." This continuous "gain of function" is a powerful piece of evidence for regulators, clinicians, and investors.

Contrary to the belief that recovery is limited to the months post-injury, NervGen's trial specifically enrolled and showed significant functional improvement in patients with chronic injuries, some a decade old. This opens a new treatment window for a large, previously overlooked patient population.

While outsiders assume walking is the ultimate recovery goal, NervGen's research reveals that regaining hand function for daily tasks like eating or using a computer is the most vital improvement for patient independence. This highlights the importance of patient-defined quality-of-life endpoints in clinical trials.

During NervGen's End-of-Phase 2 meeting, the FDA emphasized understanding the drug's real-world impact on a patient's daily life, not just the quantitative results of the primary endpoint. This signals a regulatory shift towards a more holistic, patient-centric view of therapeutic benefit in areas of high unmet need.

The science to regrow nerves and potentially treat paralysis may already be here. The primary barrier to human application is no longer the technology itself, but the immense challenge of navigating safety regulations and securing the hundreds of millions in funding required for clinical trials.